share_log

Earnings Miss: WuXi AppTec Co., Ltd. Missed EPS By 6.0% And Analysts Are Revising Their Forecasts

Earnings Miss: WuXi AppTec Co., Ltd. Missed EPS By 6.0% And Analysts Are Revising Their Forecasts

盈利不及預期:藥明康德股份有限公司每股收益低於預期6.0%,分析師正在修正他們的預測
Simply Wall St ·  10/31 06:30

The quarterly results for WuXi AppTec Co., Ltd. (SHSE:603259) were released last week, making it a good time to revisit its performance. It looks like the results were a bit of a negative overall. While revenues of CN¥10b were in line with analyst predictions, statutory earnings were less than expected, missing estimates by 6.0% to hit CN¥0.79 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

上週藥明康德股份有限公司(SHSE:603259)發佈了季度業績,現在是重新審視其表現的好時機。總體上看,結果稍微偏負。雖然100億人民幣的營業收入符合分析師的預測,但法定盈利低於預期,每股收益爲0.79人民幣,低於預期6.0%。分析師通常會在每次業績後更新其預測,我們可以從他們的估算中判斷,他們對公司的看法是否改變,或者是否有任何需要注意的新問題。因此,我們收集了最新的業績後預測,看看估值暗示着明年會發生什麼。

big
SHSE:603259 Earnings and Revenue Growth October 30th 2024
SHSE:603259 2024年10月30日的盈利和營收增長

Taking into account the latest results, the consensus forecast from WuXi AppTec's 24 analysts is for revenues of CN¥43.2b in 2025. This reflects a decent 12% improvement in revenue compared to the last 12 months. Per-share earnings are expected to shoot up 31% to CN¥3.67. Before this earnings report, the analysts had been forecasting revenues of CN¥43.3b and earnings per share (EPS) of CN¥3.70 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

考慮到最新的結果,藥明康德的24位分析師達成的共識預測是,2025年營業收入將達到432億人民幣。這相比過去12個月的營收有了可觀的12%提升。每股收益預計將大漲31%,達到3.67人民幣。在此業績之前,分析師曾預測2025年的營收爲433億人民幣,每股盈利爲3.70人民幣。因此,儘管分析師已更新他們的預測,但在最新的結果後,業務的期望並沒有發生重大變化。

There were no changes to revenue or earnings estimates or the price target of CN¥62.66, suggesting that the company has met expectations in its recent result. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values WuXi AppTec at CN¥96.12 per share, while the most bearish prices it at CN¥20.50. As you can see the range of estimates is wide, with the lowest valuation coming in at less than half the most bullish estimate, suggesting there are some strongly diverging views on how analysts think this business will perform. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.

營業收入或盈利預測、價格目標62.66人民幣均未發生變化,表明該公司在最新業績中符合預期。然而,從這些數據中我們並不只能得出這一個結論,因爲一些投資者在評估分析師的目標價時也喜歡考慮預估的價差。目前,最看好的分析師認爲藥明康德每股價值96.12人民幣,而最看淡的預估價值爲20.50人民幣。從中可以看出,估值範圍很廣,估值最低甚至不到最看好預估的一半,這表明分析師對該業務表現存在明顯分歧的看法。因此,基於共識價格目標做出決策可能並不明智,畢竟這只是對這個廣泛估值範圍的平均值。

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the WuXi AppTec's past performance and to peers in the same industry. It's pretty clear that there is an expectation that WuXi AppTec's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 9.7% growth on an annualised basis. This is compared to a historical growth rate of 25% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 13% annually. Factoring in the forecast slowdown in growth, it seems obvious that WuXi AppTec is also expected to grow slower than other industry participants.

這些估算很有趣,但在比較預測時,將其與藥明康德過去的表現以及同行業中的同行進行更廣泛的對比可能更有用。很明顯,人們預期藥明康德的營業收入增長將大幅放緩,預計到2025年底,年均增長率將顯示9.7%增長。這與過去五年的歷史增長率25%相比。將此與行業內其他公司(根據分析師預測)進行比較,他們預計年均營業收入增長率爲13%。考慮到增長放緩的預測,藥明康德也預計增長速度將低於其他行業參與者。

The Bottom Line

最重要的事情是分析師增加了它對下一年每股虧損的估計。令人欣慰的是,營收預測未發生重大變化,業務仍有望比整個行業增長更快。共識價格目標穩定在28.50美元,最新估計不足以對價格目標產生影響。

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that WuXi AppTec's revenue is expected to perform worse than the wider industry. The consensus price target held steady at CN¥62.66, with the latest estimates not enough to have an impact on their price targets.

最重要的是,沒有情緒上的重大變化,分析師再次確認業務業績與他們先前的每股收益估算相符。幸運的是,分析師還確認了他們的營業收入估算,表明其與預期符合。儘管我們的數據顯示,藥明康德的營業收入預計表現將不如更廣泛的行業。共識價格目標保持在CN¥62.66,最新估算不足以對其價格目標產生影響。

With that in mind, we wouldn't be too quick to come to a conclusion on WuXi AppTec. Long-term earnings power is much more important than next year's profits. We have forecasts for WuXi AppTec going out to 2026, and you can see them free on our platform here.

考慮到這一點,我們不應該過快得出對藥明康德的結論。長期盈利能力比明年的利潤更重要。我們對藥明康德的預測延伸至2026年,您可在我們平台上免費查看。

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for WuXi AppTec that you should be aware of.

不要忘記仍然存在風險。例如,我們已經確定了藥明康德的1個警示信號,您應該注意。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論